Protara Therapeutics
TARA
39 hedge funds and large institutions have $47.1M invested in Protara Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
8% more funds holding
Funds holding: 36 → 39 (+3)
8% more capital invested
Capital invested by funds: $43.7M → $47.1M (+$3.41M)
5.04% more ownership
Funds ownership: 56.16% → 61.2% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less call options, than puts
Call options by funds: $11K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.62M |
| 2 |
DAM
DLD Asset Management
New York
|
+$1.58M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$631K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$565K |
| 5 |
Two Sigma Investments
New York
|
+$409K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.38M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$407K |
| 3 |
Renaissance Technologies
New York
|
-$352K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$166K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$137K |
TARA Hedge Fund Activity: Q4 2021 in Review
39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2021, worth a combined $47.1M — up 7.8% from $43.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TARA positions and 4 closed out — a net gain of 4 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was OrbiMed, adding an estimated $2.62M. The largest seller was Ikarian Capital, cutting an estimated $1.38M.
- 39 institutional investors held Protara Therapeutics (TARA) as of Q4 2021, up from 36 in Q3 2021.
- Funds reported $47.1M of Protara Therapeutics stock for Q4 2021, up 7.8% quarter-over-quarter.
- 8 funds opened new Protara Therapeutics positions in Q4 2021 and 4 closed out, a net change of +4 holders.
- The largest Protara Therapeutics buyer in Q4 2021 was OrbiMed, an estimated $2.62M added.
- The largest Protara Therapeutics seller in Q4 2021 was Ikarian Capital, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2021.